Clinical Trials Browser

Osteosarcoma

NCT05022797 2024-05-13

Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

Phase 2 Terminated

3 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Drug-Related Side Effects and Adverse Reactions

NCT05899751 2024-05-10

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

Unknown

1,000 enrolled

GenitourinaryOther hematologic neoplasmSarcoma

Osteosarcoma, Water Intoxication, Hematologic Neoplasms, Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions

NCT04668768 2024-03-22

HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma

Phase 2 Suspended

3 enrolled

Lymphoid

Lymphoma

NCT00634504 2022-06-06

LVPK

Phase 1 Completed

20 enrolled 9 charts

LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Osteosarcoma, Renal Insufficiency

NCT01305655 2018-09-28

NOPHOCPG2

Phase 3 Completed

47 enrolled 5 charts

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02022358 2015-06-04

Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?

Phase 2 Terminated

34 enrolled

OtherSarcoma

Osteosarcoma, Mucositis

NCT00018967 2015-04-30

Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate

Phase NA Completed

10 enrolled

Neurotoxicity Syndromes

NCT00634322 2014-09-15

High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma

Phase 2 Terminated

7 enrolled 7 charts

Sarcoma

Osteosarcoma

NCT00219791 2014-09-11

Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance

Phase 2 Completed

Neoplasms, Renal Insufficiency

NCT00727831 2014-01-27

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Phase 1/2 Completed

4 enrolled

LymphoidOther

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Neurotoxicity Syndromes, Mucositis

NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

Approved for marketing

LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

NCT00424645 2012-12-06

Voraxaze for Delayed Methotrexate Clearance

Phase 1/2 Terminated

3 enrolled 2 charts

Other hematologic neoplasm

Hematologic Neoplasms

Clinical Trials

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma

LVPK

NOPHOCPG2

Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?

Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate

High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma

Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

Voraxaze for Delayed Methotrexate Clearance